KR20240014052A - 면역 세포의 종양내 침윤을 허용하는 방법 - Google Patents

면역 세포의 종양내 침윤을 허용하는 방법 Download PDF

Info

Publication number
KR20240014052A
KR20240014052A KR1020237040576A KR20237040576A KR20240014052A KR 20240014052 A KR20240014052 A KR 20240014052A KR 1020237040576 A KR1020237040576 A KR 1020237040576A KR 20237040576 A KR20237040576 A KR 20237040576A KR 20240014052 A KR20240014052 A KR 20240014052A
Authority
KR
South Korea
Prior art keywords
cancer
individual
metastatic
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237040576A
Other languages
English (en)
Korean (ko)
Inventor
마리오 필리온
Original Assignee
알레시아 바이오쎄라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알레시아 바이오쎄라퓨틱스 인코포레이티드 filed Critical 알레시아 바이오쎄라퓨틱스 인코포레이티드
Publication of KR20240014052A publication Critical patent/KR20240014052A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020237040576A 2021-04-27 2021-04-27 면역 세포의 종양내 침윤을 허용하는 방법 Pending KR20240014052A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2021/050572 WO2022226623A1 (en) 2021-04-27 2021-04-27 Method for allowing immune cells infiltration in tumors

Publications (1)

Publication Number Publication Date
KR20240014052A true KR20240014052A (ko) 2024-01-31

Family

ID=83846453

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237040576A Pending KR20240014052A (ko) 2021-04-27 2021-04-27 면역 세포의 종양내 침윤을 허용하는 방법
KR1020237040565A Pending KR20240013743A (ko) 2021-04-27 2022-04-26 면역 세포의 종양내 침윤을 허용하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237040565A Pending KR20240013743A (ko) 2021-04-27 2022-04-26 면역 세포의 종양내 침윤을 허용하는 방법

Country Status (10)

Country Link
US (2) US20240199758A1 (https=)
EP (2) EP4329801A4 (https=)
JP (2) JP2024516416A (https=)
KR (2) KR20240014052A (https=)
CN (2) CN117479955A (https=)
AU (2) AU2021442702A1 (https=)
CA (2) CA3173786A1 (https=)
IL (2) IL307954A (https=)
MX (2) MX2023012766A (https=)
WO (2) WO2022226623A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3173786A1 (en) * 2021-04-27 2022-10-27 Mario Filion Method for allowing immune cells infiltration in tumors
MX2024009671A (es) * 2022-02-07 2024-08-19 Alethia Biotherapeutics Inc Terapia de combinación para uso en el tratamiento del cáncer de pulmón de células no pequeñas.
CN118914553B (zh) * 2024-07-22 2025-03-18 西安医学院第一附属医院 一种结直肠腺瘤和结直肠癌早期筛查的生物标志物的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1882A (en) 1872-12-11 Angus. Campbell A towel hanger
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
EA034462B1 (ru) 2009-11-24 2020-02-11 Алетиа Байотерапьютикс Инк. Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
US9822170B2 (en) * 2012-02-22 2017-11-21 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
CA3173786A1 (en) * 2021-04-27 2022-10-27 Mario Filion Method for allowing immune cells infiltration in tumors

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Al-Lazikani et al., Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 273:927-948, 1997.
Andrew C.R. Martin, Antibody Engineering Vol. 2, Chapter 3: Protein Sequence and Structure Analysis of Antibody Variable Domains. R. Kontermann and S. Dubel (eds.), DOI 10.1007/978-3-642-01147-4_3, # Springer-Verlag Berlin Heidelberg 2010
Brochet et al. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucl Acids Res 36:W503-W508, 2008.
Cristiano Ferrario, Julie Laurin, Leon Van Kempen, Caroline Lambert, Alan Spatz, Oksana Markova, Gerald Batist, Adrian Langleben, Mario Filion, Jacques Jolivet. Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl): Abstract nr CT098. doi:10.1158/1538-7445.AM2017-CT098.
Hodge, J.W. Garnett, C.T., Farsaci, B., et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int. J. Cancer. 133: 624-636 (2013).
Jiang X, Dudzinski S, Beckermann KE, et al. MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy. Journal for ImmunoTherapy of Cancer 2020;8:e000328. doi:10.1136/ jitc-2019-000328.
Lenferink, A., Cantin, C., Nantel, A. et al. Transcriptome profiling of a TGF-β-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodies. Oncogene 29: 831-844 (2010).
MacCallum, R. M., Martin, A. C. R. and Thornton, J. T. 'Antibody-antigen interactions: Contact analysis and binding site topography' J. Mol. Biol. 262:732-745, 1996.
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)" E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij; Eur J Cancer, 45 (2009) 228 -24.
Shibue, T., Weinberg, R. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol 14: 611-629 (2017).
Terry, S., Savagner, P., Ortiz-Cuaran, S., Mahjoubi, L., Saintigny, P., Thiery, J.-P. and Chouaib, S., New insights into the role of EMT in tumor immune escape. Mol Oncol, 11: 824-846 (2017).
Wu and Kabat, An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J Exp Med 132:211-250, 1993.

Also Published As

Publication number Publication date
AU2021442702A1 (en) 2023-11-30
KR20240013743A (ko) 2024-01-30
WO2022226637A1 (en) 2022-11-03
EP4329801A1 (en) 2024-03-06
IL307961A (en) 2023-12-01
CN117479955A (zh) 2024-01-30
CA3173786A1 (en) 2022-10-27
EP4329802A1 (en) 2024-03-06
IL307954A (en) 2023-12-01
CA3173797A1 (en) 2023-10-05
AU2022266854A9 (en) 2023-12-07
JP2024516416A (ja) 2024-04-15
AU2022266854A1 (en) 2023-11-30
EP4329802A4 (en) 2025-09-03
EP4329801A4 (en) 2025-05-14
JP2024516818A (ja) 2024-04-17
MX2023012766A (es) 2024-02-23
US20240199758A1 (en) 2024-06-20
WO2022226623A1 (en) 2022-11-03
CN117479956A (zh) 2024-01-30
US20240317884A1 (en) 2024-09-26
MX2023012768A (es) 2023-11-13

Similar Documents

Publication Publication Date Title
JP7573062B2 (ja) がん治療における化学療法剤と組み合わせた抗ｆｇｆｒ２抗体
KR102777244B1 (ko) 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
CN106573977B (zh) 针对ceacam1的人源化抗体
KR20170074962A (ko) 암에 대한 조합 요법
TW201731527A (zh) 使用抗ｐｄ－１抗體與抗ｃｌｔａ－４抗體之組合以治療肺癌
US12565528B2 (en) LAG-3 antagonist therapy for lung cancer
KR20240013743A (ko) 면역 세포의 종양내 침윤을 허용하는 방법
JP2022527334A (ja) 腫瘍を処置するための抗ｃｄ７３、抗ｐｄ－ｌ１抗体及び化学療法
KR20240038008A (ko) 암 치료 방법 및 조성물
KR20240028452A (ko) 암을 치료하기 위한 방법 및 조성물
WO2024137776A1 (en) Combination therapy for lung cancer
JP2024511977A (ja) 抗ｉｌｔ３抗体によるがんの治療方法
WO2025036445A1 (en) Treatment of lung cancer with anti-pd-1 and chemotherapy
HK40109234A (zh) 用於治疗癌症的方法和组合物
KR20260054704A (ko) 항-pd-1 및 화학요법을 이용한 폐암 치료
KR20250112805A (ko) 항-ddr1 항체 및 면역관문 억제제를 사용한 암 치료 방법
KR20250115399A (ko) 항-ddr1 항체를 사용한 암 치료 방법
TW202523693A (zh) 手術前後基於抗ｐｄ－１之治療
HK40110052A (zh) 用於治疗癌症的方法和组合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902